» Articles » PMID: 29688465

Low Incidence of Dysplasia and Colorectal Cancer Observed Among Inflammatory Bowel Disease Patients with Prolonged Colonic Diversion

Abstract

Background: In inflammatory bowel disease (IBD), many scenarios call for fecal diversion, leaving behind defunctionalized bowel. The theoretical risk of colorectal cancer (CRC) in this segment is frequently cited as a reason for resection. To date, no studies have characterized the incidence of neoplasia in the diverted colorectal segments of IBD patients.

Methods: A retrospective cohort analysis was conducted for IBD patients identified through a tertiary care center pathology database. Patients that had undergone colorectal diversion and were diverted for ≥ 1 year were included. Incidence of diverted dysplasia/CRC was calculated for Crohn's disease (CD) and ulcerative colitis (UC) with respect to diverted patient-years (dpy) and patient-years of disease (pyd).

Results: In total, 154 patients comprising 754 dpy and 1984 pyd were analyzed. Only 2 cases of diverted colorectal dysplasia (CD 1, UC 1) and 1 case of diverted CRC (UC) were observed. In the UC cohort (n = 75), the rate of diversion-associated CRC was 4.5 cases/1000 dpy (95% CI 0.11-25/1000) or 1.5 cases/1000 pyd (95% CI 0.04-8.2/1000). In the CD cohort (n = 79), no patients developed CRC, although a dysplasia rate of 1.9 cases/1000 dpy (95% CI 0.05-11/1000) or 0.77 cases/1000 pyd (95% CI 0.02-4.3/1000) was observed. All patients developing neoplasia had disease duration > 10 years and microscopic inflammation.

Conclusions: Diverted dysplasia occurred infrequently with rates overlapping those reported in registries for IBD-based rectal cancers. Neoplasia was undetected in patients with < 10 pyd, regardless of diversion duration, suggesting low yield for endoscopic surveillance before this time.

Citing Articles

Correlation of Serum CA242, CA724, and TPA Levels with Clinicopathological Features and Prognosis in Patients with Inflammatory Bowel Disease Complicated with Rectal Cancer.

Liang H, Yang X J Oncol. 2022; 2022:7742760.

PMID: 36245974 PMC: 9553515. DOI: 10.1155/2022/7742760.


Diversion proctocolitis and the problem of the forgotten rectum in inflammatory bowel diseases: A systematic review.

Dal Buono A, Carvello M, Sachar D, Spinelli A, Danese S, Roda G United European Gastroenterol J. 2021; 9(10):1157-1167.

PMID: 34845854 PMC: 8672074. DOI: 10.1002/ueg2.12175.


Clinicopathological and prognostic evaluations of anorectal cancer after fecal diversion for patients with Crohn's disease.

Kuroki H, Sugita A, Koganei K, Tatsumi K, Futatsuki R, Nakao E BMC Gastroenterol. 2021; 21(1):168.

PMID: 33849449 PMC: 8045380. DOI: 10.1186/s12876-021-01751-3.


Risk of Colorectal Cancer in Ulcerative Colitis Patients: A Systematic Review and Meta-Analysis.

Zhou Q, Shen Z, Wu B, Xu C, He Z, Chen T Gastroenterol Res Pract. 2019; 2019:5363261.

PMID: 31781191 PMC: 6874962. DOI: 10.1155/2019/5363261.

References
1.
Eaden J, Abrams K, Mayberry J . The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001; 48(4):526-35. PMC: 1728259. DOI: 10.1136/gut.48.4.526. View

2.
Yamamoto T, Keighley M . Long-term outcome of total colectomy and ileostomy for Crohn disease. Scand J Gastroenterol. 1999; 34(3):280-6. DOI: 10.1080/00365529950173690. View

3.
Winther K, BRUUN E, Federspiel B, Guldberg P, Binder V, Brynskov J . Screening for dysplasia and TP53 mutations in closed rectal stumps of patients with ulcerative colitis or Crohn disease. Scand J Gastroenterol. 2004; 39(3):232-7. DOI: 10.1080/00365520310008368. View

4.
Jess T, Simonsen J, Jorgensen K, Pedersen B, Nielsen N, Frisch M . Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology. 2012; 143(2):375-81.e1. DOI: 10.1053/j.gastro.2012.04.016. View

5.
Sengupta N, Yee E, Feuerstein J . Colorectal Cancer Screening in Inflammatory Bowel Disease. Dig Dis Sci. 2015; 61(4):980-9. DOI: 10.1007/s10620-015-3979-z. View